SANGAMO THERAPEUTICS, INC.: operating cash flow
Operating cash flow for SANGAMO THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All SANGAMO THERAPEUTICS, INC. financial histories
What this measure means
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2009-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -97,208,000 | USD | 2026-03-30 | 10-K · 0001628280-26-022029 |
| 2024-01-01 | 2024-12-31 | -67,139,000 | USD | 2026-03-30 | 10-K · 0001628280-26-022029 |
| 2023-01-01 | 2023-12-31 | -224,842,000 | USD | 2025-03-17 | 10-K · 0001628280-25-013088 |
| 2022-01-01 | 2022-12-31 | -223,627,000 | USD | 2024-03-13 | 10-K · 0001628280-24-010788 |
| 2021-01-01 | 2021-12-31 | -233,251,000 | USD | 2024-03-13 | 10-K · 0001628280-24-010788 |
| 2020-01-01 | 2020-12-31 | 169,875,000 | USD | 2023-02-23 | 10-K · 0001628280-23-004666 |
| 2019-01-01 | 2019-12-31 | -144,402,000 | USD | 2022-02-24 | 10-K · 0001628280-22-003819 |
| 2018-01-01 | 2018-12-31 | 36,550,000 | USD | 2021-02-24 | 10-K · 0001628280-21-003069 |
| 2017-01-01 | 2017-12-31 | 11,179,000 | USD | 2020-02-28 | 10-K · 0001628280-20-002582 |
| 2016-01-01 | 2016-12-31 | -65,883,000 | USD | 2019-03-01 | 10-K · 0001564590-19-005808 |
| 2013-01-01 | 2013-12-31 | -19,482,000 | USD | 2014-02-24 | 10-K · 0001193125-14-065170 |
| 2012-01-01 | 2012-12-31 | -8,082,000 | USD | 2014-02-24 | 10-K · 0001193125-14-065170 |
| 2011-01-01 | 2011-12-31 | -25,895,000 | USD | 2014-02-24 | 10-K · 0001193125-14-065170 |
| 2010-01-01 | 2010-12-31 | -23,934,000 | USD | 2013-02-26 | 10-K · 0001193125-13-076887 |
| 2009-01-01 | 2009-12-31 | -6,137,000 | USD | 2012-02-23 | 10-K · 0001193125-12-073470 |
Related financial histories
- SANGAMO THERAPEUTICS, INC.: total assets
- SANGAMO THERAPEUTICS, INC.: total liabilities
- SANGAMO THERAPEUTICS, INC.: stockholders equity
- SANGAMO THERAPEUTICS, INC.: cash and cash equivalents
- SANGAMO THERAPEUTICS, INC.: net income or loss
- SANGAMO THERAPEUTICS, INC.: capital expenditure payments
- SANGAMO THERAPEUTICS, INC.: revenue
- SANGAMO THERAPEUTICS, INC.: contract revenue excluding tax
- SANGAMO THERAPEUTICS, INC.: financing cash flow
- SANGAMO THERAPEUTICS, INC.: investing cash flow
- SANGAMO THERAPEUTICS, INC.: retained earnings or deficit
- SANGAMO THERAPEUTICS, INC.: basic weighted-average shares
- SANGAMO THERAPEUTICS, INC.: diluted weighted-average shares
- SANGAMO THERAPEUTICS, INC.: basic earnings per share
- SANGAMO THERAPEUTICS, INC.: diluted earnings per share
- SANGAMO THERAPEUTICS, INC.: income tax expense or benefit
- SANGAMO THERAPEUTICS, INC.: net property, plant and equipment
- SANGAMO THERAPEUTICS, INC.: share-based compensation expense
- SANGAMO THERAPEUTICS, INC.: operating income or loss
- SANGAMO THERAPEUTICS, INC.: current assets
- SANGAMO THERAPEUTICS, INC.: current liabilities
- SANGAMO THERAPEUTICS, INC.: current accounts payable
- SANGAMO THERAPEUTICS, INC.: goodwill carrying amount
- SANGAMO THERAPEUTICS, INC.: net current accounts receivable
- SANGAMO THERAPEUTICS, INC.: operating expenses
- SANGAMO THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- SANGAMO THERAPEUTICS, INC. / CIK 0001001233
- Captured
- 2026-09-20T05:11:11.650Z
- SEC response SHA-256
f678a4cd3364c095e387026eb9f115ac294a4697b3c5aebe6c86663002f694af
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001001233.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))